Eli Lilly LLY Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Eli Lilly in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Eli Lilly's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Eli Lilly's cash & equivalents?
- Eli Lilly (LLY) reported cash & equivalents of $5.28B in Q1 2026.
- How has Eli Lilly's cash & equivalents changed year-over-year?
- Eli Lilly's cash & equivalents increased by 70.8% year-over-year, from $3.09B to $5.28B.
- What is the long-term trend for Eli Lilly's cash & equivalents?
- Over 5 years (2020 to 2025), Eli Lilly's cash & equivalents has grown at a 14.7% compound annual growth rate (CAGR), from $3.66B to $7.27B.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.